CYB 003
Alternative Names: CYB-003; Deuterated psilocin - Cybin; Deuterated-Psilocin - CybinLatest Information Update: 28 May 2025
At a glance
- Originator Cybin
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- No development reported Alcoholism; Psychiatric disorders
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Alcoholism in Canada (PO)
- 08 May 2025 Cybin has patent protection for CYB 003 for Major depressive disorder in USA
- 28 Mar 2025 No recent reports of development identified for preclinical development in Psychiatric-disorders in Canada (PO, Tablet)